| Recruiting | Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r A Acute Myeloid Leukemia (AML) | Phase 3 | 2025-09-26 |
| Recruiting | A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors ( Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm | Phase 1 | 2025-03-27 |
| Recruiting | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia AML, AML With Mutated NPM1, Hematologic Malignancy | Phase 1 | 2024-02-22 |
| Recruiting | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | Phase 1 | 2023-10-18 |
| Recruiting | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, V Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML | Phase 1 | 2023-07-18 |
| Withdrawn | Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer NSCLC | Phase 1 | 2023-02-01 |
| Completed | Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carci HNSCC | Phase 1 / Phase 2 | 2021-12-07 |
| Terminated | Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies Advanced Solid Tumor | Phase 1 | 2021-05-06 |
| Recruiting | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia | Phase 1 / Phase 2 | 2019-09-12 |
| Completed | Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response t HRAS Gene Mutation, HNSCC | Phase 2 | 2019-03-15 |
| Terminated | First-in-Human Study of KO-947 in Non-Hematological Malignancies Advanced Malignant Neoplasm | Phase 1 | 2017-04-06 |
| Completed | Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia Leukemia, Myelomonocytic, Chronic | Phase 2 | 2017-01-10 |
| Terminated | Tipifarnib in Subjects With Myelodysplastic Syndromes Myelodysplastic Syndromes | Phase 2 | 2016-06-01 |
| Completed | Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Resp Relapsed or Refractory Peripheral T-Cell Lymphoma | Phase 2 | 2016-02-25 |
| Completed | Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations Thyroid Cancer, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), HRAS Mutant Tumor | Phase 2 | 2015-05-13 |
| Available | Expanded Access to Tipifarnib HRAS Mutations or Peripheral T Cell Lymphoma (PTCL) | — | — |
| Available | Expanded Access to Ziftomenib Acute Lymphoblastic Leukemia, With Appropriate Mutations, Acute Myeloid Leukemia, With NPM1 Mutations | — | — |